Key result
Fenofibrate prevented diabetes-induced cardiac dysfunction, inflammation, and remodelling in wild-type Type 1 diabetic mice by increasing FGF21 and up-regulating Sirt1-mediated autophagy.
Why the study?
Does fenofibrate prevent cardiac dysfunction and remodelling in Type 1 diabetic mice?
Does fenofibrate prevent cardiac dysfunction and remodelling in Type 1 diabetic mice?
Fenofibrate prevents Type 1 diabetes-induced cardiac dysfunction and remodelling in mice via an FGF21/Sirt1-mediated increase in autophagy.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for fenofibrate in diabetic cardiomyopathy; prospective human studies required before clinical use.
Zhang et al. (2016) studied Type 1 diabetes. Fenofibrate vs. vehicle was evaluated on diabetes-induced cardiac dysfunction, inflammation and remodelling. Fenofibrate prevented diabetes-induced cardiac dysfunction, inflammation, and remodelling in wild-type Type 1 diabetic mice by increasing FGF21 and up-regulating Sirt1-mediated autophagy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: